Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8α.
Anderson VE, Brilha SS, Weber AM, Pachnio A, Wiedermann GE, Dauleh S, Ahmed T, Pope GR, Quinn LL, Docta RY, Quattrini A, Masters S, Cartwright N, Viswanathan P, Melchiori L, Rice LV, Sevko A, Gueguen C, Saini M, Tavano B, Abbott RJM, Silk JD, Laugel B, Sanderson JP, Gerry AB. Anderson VE, et al. Among authors: abbott rjm. J Immunother. 2023 May 1;46(4):132-144. doi: 10.1097/CJI.0000000000000456. Epub 2023 Feb 27. J Immunother. 2023. PMID: 36826388 Free PMC article.
Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy.
Sanderson JP, Crowley DJ, Wiedermann GE, Quinn LL, Crossland KL, Tunbridge HM, Cornforth TV, Barnes CS, Ahmed T, Howe K, Saini M, Abbott RJ, Anderson VE, Tavano B, Maroto M, Gerry AB. Sanderson JP, et al. Oncoimmunology. 2019 Nov 24;9(1):1682381. doi: 10.1080/2162402X.2019.1682381. eCollection 2020. Oncoimmunology. 2019. PMID: 32002290 Free PMC article.
Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
Silk JD, Abbott RJM, Adams KJ, Bennett AD, Brett S, Cornforth TV, Crossland KL, Figueroa DJ, Jing J, O'Connor C, Pachnio A, Patasic L, Peredo CE, Quattrini A, Quinn LL, Rust AG, Saini M, Sanderson JP, Steiner D, Tavano B, Viswanathan P, Wiedermann GE, Wong R, Jakobsen BK, Britten CM, Gerry AB, Brewer JE. Silk JD, et al. Among authors: abbott rjm. J Immunol. 2022 Jan 1;208(1):169-180. doi: 10.4049/jimmunol.2001357. Epub 2021 Dec 1. J Immunol. 2022. PMID: 34853077
TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer.
Kortleve D, Hammerl D, van Brakel M, Wijers R, Roelofs D, Kroese K, Timmermans MM, Liao CY, Huang S, Trapman-Jansen A, Foekens R, Michaux J, de Beijer MTA, Buschow SI, Demmers JAA, Kok M, Danen EHJ, Bassani-Sternberg M, Martens JWM, Abbott RJM, Debets R. Kortleve D, et al. Among authors: abbott rjm. Cancer Discov. 2024 Dec 2;14(12):2450-2470. doi: 10.1158/2159-8290.CD-24-0168. Cancer Discov. 2024. PMID: 39172012 Free PMC article.
Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus.
Palendira U, Low C, Bell AI, Ma CS, Abbott RJ, Phan TG, Riminton DS, Choo S, Smart JM, Lougaris V, Giliani S, Buckley RH, Grimbacher B, Alvaro F, Klion AD, Nichols KE, Adelstein S, Rickinson AB, Tangye SG. Palendira U, et al. J Exp Med. 2012 May 7;209(5):913-24. doi: 10.1084/jem.20112391. Epub 2012 Apr 9. J Exp Med. 2012. PMID: 22493517 Free PMC article.
16 results